Entero Healthcare Solutions Limited has informed the Exchange about Sale of subsidiary.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.8 pts less than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Entero Healthcare's Board, at its September 29, 2025 meeting, approved two transactions. First, the company will sell its entire 100% stake in wholly owned subsidiary Suprabhat Pharmaceutical to its erstwhile promoters for up to Rs. 37 lakh. Suprabhat is a very small part of the business, contributing just 0.39% of consolidated income and 0.01% of net worth. Second, the company will acquire a 60% stake in Ace Cardiopathy Solutions, a Delhi-based medical devices distributor, for between Rs. 59.30 crore and Rs. 77.10 crore in cash. Ace Cardiopathy is in the same line of business as Entero, with a turnover of Rs. 154.8 crore in FY25. The acquisition is not a related party transaction and is expected to close by January 31, 2026, subject to due diligence.
Net positive and strategic — Entero is offloading a tiny non-core subsidiary while buying a meaningful 60% stake in a same-industry distributor with Rs. 150+ crore turnover, which could strengthen its core medical devices distribution business and boost consolidated revenue. Shareholders should watch the final acquisition price and completion timelines for incremental upside.